AZ Restructures, But Will Changes Sideline Plans To Accelerate R&D?
Executive Summary
AstraZeneca unveiled an R&D restructuring March 18 that will consolidate research to three locations and reduce headcount by 1,600, but the company will have to be dogged in its effort to relocate key employees if it is to ensure the changes don’t disrupt its broader goal of accelerating the pace of R&D.
You may also be interested in...
BioHub At Alderley Park: A Bioincubator With A Difference
Once an R&D site for AstraZeneca, the BioHub at Alderley Park is now home to a number of emerging biotechs. Profiles of Absynth Biologics, Blueberry Therapeutics, Molplex, and OncoTherics.
Magnus Life Science Sets Up Five R&D-Centric Units At Top U.K. University
The unique industrial collaboration with University College London will exploit in-depth knowledge of blood-flow biology to develop new products for CV disease, fetal growth retardation and melanoma.
European Notebook: IPO Fever Comes To Europe; EMA Plans Adaptive Licensing Pilot Project
Pharmaceutical and biotech companies in Europe take heart from IPOs and new governmental schemes to improve patients’ early access to innovative medicines, while fresh calls are made for an integrated, over-arching European industrial strategy for the life sciences sector.